2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Lymphoma, Follicular
5
Breast Neoplasms
5
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Waldenstrom Macroglobulinemia
3
Recurrence
3
Pancreatic Neoplasms
3
Neoplasms
3
Melanoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell, Marginal Zone
3
Burkitt Lymphoma
3
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Leukemia
2
Glioma
2
Glioblastoma
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Virus Diseases
1
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Select Advanced Solid Tumors
1
Pregnancy Related
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pain
1
Neuroectodermal Tumors
1
Interventions
Temozolomide
131
Radiotherapy
87
Bevacizumab
43
Radiation
31
Carmustine
29
Magnetic Resonance Spectroscopy
22
Irinotecan
22
Erlotinib Hydrochloride
22
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gene Expression Profiling
7
Gefitinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Antibodies, Monoclonal
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled